Pages that link to "Q45878639"

The following pages link to Pharmacokinetics and safety of OBI‐1, a recombinant B domain‐deleted porcine factor VIII, in subjects with haemophilia A (Q45878639):

Displaying 32 items.

• Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies (Q26739935) (← links)
• Emerging and future therapies for hemophilia (Q26781143) (← links)
• Gene therapy for hemophilia (Q28081911) (← links)
• High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance (Q30577011) (← links)
• Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. (Q33419996) (← links)
• Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII (Q34111482) (← links)
• Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery (Q35184180) (← links)
• The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces (Q35578480) (← links)
• Key issues in inhibitor management in patients with haemophilia (Q37602415) (← links)
• Factor VIII inhibitors in hemophilia A: rationale and latest evidence (Q38101041) (← links)
• Investigational drugs for coagulation disorders (Q38106245) (← links)
• Blood Clotting Factor VIII: From Evolution to Therapy (Q38118763) (← links)
• Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A. (Q38451206) (← links)
• New products for the treatment of haemophilia (Q38604626) (← links)
• Acquired hemophilia A: Updated review of evidence and treatment guidance. (Q38805567) (← links)
• Susoctocog Alfa: A Review in Acquired Haemophilia A. (Q38813223) (← links)
• Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. (Q39027891) (← links)
• A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. (Q39648285) (← links)
• Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile (Q41478287) (← links)
• Borrowing (once again) from the animal kingdom (Q42333631) (← links)
• Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A (Q42376733) (← links)
• Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories (Q42971075) (← links)
• Alternative therapies for the management of inhibitors (Q45856195) (← links)
• Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy (Q45856991) (← links)
• Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. (Q45861084) (← links)
• Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor (Q45863975) (← links)
• Successful management of refractory haematuria with recombinant porcine factor VIII replacement for paediatric congenital haemophilia A with high-titre inhibitor. (Q45867398) (← links)
• Acquired hemophilia in malignancy (Q45879674) (← links)
• Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review (Q49988033) (← links)
• Ca(2 ) concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy. (Q53496690) (← links)
• Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A (Q60302918) (← links)
• Acquired Haemophilia A: An Intriguing Disease (Q97521342) (← links)